AgeX Therapeutics logo
AgeX Therapeutics AGE

Quarterly report 2025-Q3
added 11-13-2025

report update icon

AgeX Therapeutics Market Cap 2011-2026 | AGE

As of March 03, 2026 AgeX Therapeutics has a market cap of $ 12.2 K


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap AgeX Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
14.1 K 679 30.4 M 65.5 M 52.6 M 137 M - 132 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
137 M 679 59.7 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
2.77 B $ 20.22 -2.32 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
4.09 M $ 0.82 -3.48 % $ 4.47 M chinaChina
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Axsome Therapeutics Axsome Therapeutics
AXSM
8.67 B $ 164.71 -1.01 % $ 8.19 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
962 M $ 3.73 -2.49 % $ 1.11 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 8.5 -2.63 % $ 1.39 B britainBritain
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
3.04 B $ 23.88 - $ 2.92 B usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
94.1 M $ 18.08 1.06 % $ 868 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Certara Certara
CERT
1.08 B $ 7.19 1.93 % $ 1.15 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
114 M $ 17.72 -2.37 % $ 454 M usaUSA
Exelixis Exelixis
EXEL
11.7 B $ 40.99 -0.1 % $ 11.1 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Galapagos NV Galapagos NV
GLPG
4.42 B $ 33.13 -2.82 % $ 2.69 B belgiumBelgium
Greenwich LifeSciences Greenwich LifeSciences
GLSI
115 M $ 27.7 1.12 % $ 361 M usaUSA
Genmab A/S Genmab A/S
GMAB
25 B $ 27.67 -6.69 % $ 17.7 B danmarkDanmark
Capricor Therapeutics Capricor Therapeutics
CAPR
155 M $ 26.04 -3.07 % $ 697 M usaUSA
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
291 M $ 0.99 -2.92 % $ 72.7 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
9.66 B $ 69.39 -0.67 % $ 8.32 B usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
1.61 B $ 28.56 -1.19 % $ 1.64 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
40.9 M $ 6.3 -3.67 % $ 51.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Immuron Limited Immuron Limited
IMRN
348 M $ 0.75 -0.69 % $ 6.43 M australiaAustralia
Immatics N.V. Immatics N.V.
IMTX
503 M $ 9.86 -1.3 % $ 620 M germanyGermany
Immunic Immunic
IMUX
145 M $ 1.1 3.3 % $ 171 M usaUSA
Immunovant Immunovant
IMVT
2.26 B $ 26.99 -2.74 % $ 4.09 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Inhibrx Inhibrx
INBX
1.75 B $ 75.96 -1.97 % $ 3.58 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
1.71 M $ 0.75 -8.49 % $ 1.84 M canadaCanada
INmune Bio INmune Bio
INMB
211 M $ 1.41 6.07 % $ 25.4 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
31.6 B $ 146.89 0.39 % $ 29.2 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
215 K $ 3.19 -4.49 % $ 1.14 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
363 M $ 1.63 -1.21 % $ 235 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
1.63 B $ 29.11 -0.31 % $ 1.69 B usaUSA